Becton Dickinson and Co
NYSE:BDX
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
221.47
247.73
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one BDX stock under the Base Case scenario is 292.11 USD. Compared to the current market price of 224.25 USD, Becton Dickinson and Co is Undervalued by 23%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Becton Dickinson and Co
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for BDX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Becton Dickinson and Co. (BD) is a global leader in the medical technology sector, with a rich history tracing back to its founding in 1897. The company specializes in the development, manufacturing, and distribution of a wide array of medical devices, instrument systems, and reagents that are essential in hospitals and laboratories. BD's products play a pivotal role in improving patient outcomes by enhancing the accuracy of diagnostics and facilitating efficient pharmaceutical delivery. With a commitment to innovation, BD invests significantly in research and development, ensuring it remains at the forefront of advanced technology in healthcare, which resonates well with investors seeking s...
Becton Dickinson and Co. (BD) is a global leader in the medical technology sector, with a rich history tracing back to its founding in 1897. The company specializes in the development, manufacturing, and distribution of a wide array of medical devices, instrument systems, and reagents that are essential in hospitals and laboratories. BD's products play a pivotal role in improving patient outcomes by enhancing the accuracy of diagnostics and facilitating efficient pharmaceutical delivery. With a commitment to innovation, BD invests significantly in research and development, ensuring it remains at the forefront of advanced technology in healthcare, which resonates well with investors seeking sustainable growth in a resilient industry.
The company's diverse portfolio spans three main segments: BD Medical, BD Life Sciences, and BD Biosciences, enabling it to tap into multiple revenue streams while addressing critical healthcare needs worldwide. BD's strategic focus on expanding its presence in emerging markets, coupled with its robust pipeline of new products, positions it favorably for future growth. Additionally, BD’s commitment to operational excellence and cost management bolsters its profitability and shareholder value. For investors, BD offers a compelling opportunity as it navigates the evolving landscape of healthcare, characterized by increasing demand for high-quality medical solutions and a growing emphasis on personalized medicine. As the company continues to deliver innovative products and services while maintaining strong financial fundamentals, it remains a key player to watch in the dynamic world of medical technology.
Becton, Dickinson and Company (BD) is a global leader in medical technology, offering a broad range of products and services primarily focused on enhancing healthcare. The company's operations are typically categorized into three core business segments:
-
BD Medical:
- This segment encompasses a wide range of medical devices and supplies. BD Medical is involved in the development and manufacture of products used in medication management, surgical procedures, and disease management. Key offerings include injection devices, intravenous (IV) catheters, and other devices used for diagnostics and therapy.
-
BD Life Sciences:
- This segment focuses on product offerings and services that aid in the collection and processing of biological samples. BD Life Sciences includes instruments, reagents, and consumables that are essential for microbiology, molecular diagnostics, and the development and manufacture of biopharmaceuticals. The segment plays a significant role in supporting laboratories and healthcare professionals in diagnostics and research.
-
BD Biosciences:
- BD Biosciences specializes in tools and services for researchers in the life sciences sector, particularly in the areas of cell biology, immunology, and molecular biology. This segment provides flow cytometry instruments, reagents, and software that assist in cell sorting and analysis, facilitating vital research in clinical labs and academic institutions.
These core segments allow BD to maintain a comprehensive portfolio that addresses the needs of a variety of healthcare environments, thereby positioning the company as a significant player in the global medical technology landscape. Each segment is geared toward innovation, with a focus on improving patient outcomes and enhancing the efficiency of healthcare delivery.
Becton Dickinson and Company (BD) has several unique competitive advantages that help position it favorably in the medical technology and healthcare sectors:
-
Strong Brand Reputation: BD has a long-standing history and a solid reputation for quality and reliability in medical devices and laboratory equipment. This brand equity engenders trust among healthcare providers and institutions, which can be a significant barrier to entry for new competitors.
-
Broad Product Portfolio: BD offers a diverse range of products and solutions, including biosciences, medication management, and infection prevention. This extensive product lineup allows the company to cater to various market segments and customer needs, helping to reduce reliance on any single product category.
-
Innovation and R&D Investment: BD consistently invests a significant portion of its revenue into research and development. This commitment to innovation enables the company to stay ahead in technology advancements and product development, ensuring it can meet evolving healthcare needs.
-
Global Reach and Distribution Network: With a presence in over 190 countries, BD has a well-established global distribution network. This allows for efficient logistics and supply chain management, enabling the company to respond quickly to local market demands and expand into emerging markets.
-
Regulatory Expertise: Navigating the complex regulatory landscape of medical devices and pharmaceuticals is a critical competency. BD's extensive experience in obtaining regulatory approvals and understanding compliance requirements gives it an advantage over less experienced competitors.
-
Strategic Acquisitions: BD has a history of acquiring complementary businesses and technologies that enhance its product range and market position. These strategic acquisitions allow the company to quickly integrate new capabilities and expand its customer base.
-
Strong Customer Relationships: BD has built long-term relationships with healthcare providers, hospitals, and laboratories, which often leads to repeat business and customer loyalty. This relationship-centric approach can provide a competitive edge over firms that lack similar connections.
-
Focus on Sustainability: BD has made strides towards sustainable practices, which aligns with the growing trend of environmentally conscious healthcare solutions. This can strengthen brand loyalty and attract customers who prioritize sustainability in their operations.
-
Scale of Operations: The company's large scale enables it to benefit from economies of scale, reducing costs and improving margins compared to smaller competitors. This financial robustness provides BD with greater flexibility to invest in innovation and market penetration.
-
End-to-End Solutions: BD differentiates itself by providing complete solutions, from product development to end-user support, offering an integrated experience. This holistic approach can enhance customer satisfaction and increases the switching costs for institutions reliant on BD's comprehensive offerings.
These competitive advantages collectively strengthen BD's market position and provide a robust defense against competitive pressures in the medical technology industry.
Becton Dickinson and Company (BD) faces several risks and challenges in the near future, which can impact its business operations and market position. Here are some key factors:
-
Regulatory Changes: BD operates in a highly regulated industry. Changes in healthcare regulations, such as the Affordable Care Act in the U.S. and the Medical Device Regulation in the EU, could affect product approval processes, market access, and compliance costs.
-
Supply Chain Disruptions: The global supply chain has been under significant pressure, particularly due to the COVID-19 pandemic. Disruptions in the supply of raw materials and components can lead to manufacturing delays and increased costs.
-
Competition: The medical device and diagnostics market is highly competitive. BD faces competition from both established players and innovative startups, which can erode market share and pressure pricing.
-
Technological Advancements: Rapid advancements in technology require BD to continually invest in research and development to stay competitive. Failing to keep up with technological trends can lead to loss of market position.
-
Pricing Pressure: Healthcare providers are under financial strain, leading to more negotiation power regarding pricing. BD may face pressure to reduce prices, which could impact margins.
-
Class Action Lawsuits and Liability Risks: Like many companies in the medical field, BD may face legal challenges related to product liability or potential safety issues, which can lead to financial losses and damage to reputation.
-
Market Demand Fluctuations: The demand for certain medical devices and diagnostics can change due to factors like pandemics or changes in healthcare practices. BD must adapt quickly to shifting market needs.
-
Foreign Exchange Risks: BD has a global presence and is exposed to foreign exchange fluctuations, which can impact profitability when revenues from international sales are converted back to U.S. dollars.
-
Sustainability and ESG Concerns: There is increasing pressure on companies to adhere to environmental, social, and governance (ESG) standards. BD may face challenges in meeting these expectations, impacting reputation and customer loyalty.
-
Global Economic Conditions: Economic downturns or instability in key markets can affect healthcare spending, and consequently, the demand for BD’s products.
Navigating these risks will require BD to continue being agile and proactive in its strategic planning, maintaining strong relationships with stakeholders, and investing in innovation and compliance.
Revenue & Expenses Breakdown
Becton Dickinson and Co
Balance Sheet Decomposition
Becton Dickinson and Co
Current Assets | 10.5B |
Cash & Short-Term Investments | 2.2B |
Receivables | 3B |
Other Current Assets | 5.3B |
Non-Current Assets | 46.8B |
PP&E | 6.8B |
Intangibles | 37.4B |
Other Non-Current Assets | 2.6B |
Current Liabilities | 8.9B |
Other Current Liabilities | 8.9B |
Non-Current Liabilities | 22.4B |
Long-Term Debt | 17.9B |
Other Non-Current Liabilities | 4.5B |
Earnings Waterfall
Becton Dickinson and Co
Revenue
|
20.2B
USD
|
Cost of Revenue
|
-11B
USD
|
Gross Profit
|
9.2B
USD
|
Operating Expenses
|
-6.3B
USD
|
Operating Income
|
2.9B
USD
|
Other Expenses
|
-1.2B
USD
|
Net Income
|
1.7B
USD
|
Free Cash Flow Analysis
Becton Dickinson and Co
USD | |
Free Cash Flow | USD |
Becton Dickinson (BD) reported solid Q4 results with 7.4% revenue growth and expanded margins. For FY 2025, the company expects total revenues between $21.9 billion and $22.1 billion, reflecting 8.8% to 9.3% currency-neutral growth. Key drivers include an anticipated 4% to 4.5% organic growth, boosted by the Advanced Patient Monitoring acquisition. BD targets a 10% increase in adjusted EPS, aiming to expand adjusted operating margins by 100 basis points. While navigating market challenges in China, BD remains optimistic about long-term growth, maintaining a focus on innovation and operational excellence.
What is Earnings Call?
BDX Profitability Score
Profitability Due Diligence
Becton Dickinson and Co's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Score
Becton Dickinson and Co's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
BDX Solvency Score
Solvency Due Diligence
Becton Dickinson and Co's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Score
Becton Dickinson and Co's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BDX Price Targets Summary
Becton Dickinson and Co
According to Wall Street analysts, the average 1-year price target for BDX is 283.5 USD with a low forecast of 252.48 USD and a high forecast of 340.33 USD.
Dividends
Current shareholder yield for BDX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
BDX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Becton, Dickinson & Co. is a medical technology company. The company is headquartered in Franklin Lakes, New Jersey and currently employs 75,000 full-time employees. The firm operates through three business segments: BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including medication delivery solutions, medication management solutions, diabetes care and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
Contact
IPO
Employees
Officers
The intrinsic value of one BDX stock under the Base Case scenario is 292.11 USD.
Compared to the current market price of 224.25 USD, Becton Dickinson and Co is Undervalued by 23%.